Approval for addition of enhanced sonication, a detachable cradle, and several other modifications to the exablate 2000 system.  The device, as modified, will be marketed under the trade name exablate 2100 and is indicated for ablation of uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure and whose uterine size is less than 24 weeks.  Patients should have completed child bearing.